Verrica Q2 2024: YCANTH revenue $4.9M; net loss $17.2M; positive Phase 2 BCC data

Verrica Pharmaceuticals Inc.

2024-Q2 EPS reported -$0.81 revenue$9,003,000

Net product revenue of $4.9M from YCANTH; net loss $17.2M ($0.37/sh) vs $11.0M ($0.24/sh) in Q2 2023.
Cash and equivalents $31.9M; expects runway into Q1 2025.
Phase 2 VP-315: 51% complete histologic clearance of basal cell carcinoma; no serious adverse events.
Permanent J-Code for YCANTH effective Apr 1; settlement with Dormer Labs to stop unapproved cantharidin sales in US.
Amended Torii agreement: equal cost split for Phase 3 common warts trial; $8M milestone at first Japan patient dosed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.